Moving Pharma Forward

Impact-Focused Thought Partners

About us

Protagoras Group is a London-based boutique life science consultancy, founded to support our clients in driving innovation throughout all aspects of their business.

We have worked with life science companies of all sizes, ranging from early-stage startups right through to top-ten Pharma. While our experience and industry knowledge matches other consultancies, our true differentiation lies in our collaborative, client-focused approach.

Our mission is to do impactful work and with every project we do, we seek to bring real value to our clients’ organisations. We work the way our clients need us to, building truly customised solutions to meet our clients’ needs – that’s why every client we have worked with continues to work with us long-term.

Why us?
Why us?
How we help

Our deep industry experience across strategy and implementation allows us to “Advise, Build and Change” client organisations effectively.

Our approach to consulting is simple. Helping our clients develop their strategy allows us to better build and implement the resultant solutions. In turn, understanding how these solutions are put into practice helps us to refine the strategies we develop.

What we offer

By keeping our focus clear within the Pharma & Life Sciences industry, we offer real depth of knowledge to our clients, ensuring executive teams have the right level of support they need to make informed decisions.

We work across the operating model to improve effectiveness, we support in building pharmaceutical assets’ development strategy across the product lifecycle, and we support BioTech companies throughout the readiness roadmap.

Our team

The Protagoras Team has wide-ranging experience within the Life Sciences sector.

Our latest white paper

Trial decentralisation: The benefits and challenges
Trial decentralisation: The benefits and challenges

Over the course of the pandemic the use of Decentralised Clinical Trials (DCT) increased significantly, with around 87% of sponsors and contract research organisations conducting or planning to conduct trials with decentralised aspects – compared to 28% prior to the pandemic. The primary driver for this shift was to avoid delays in clinical trials that included vulnerable patients that were unwilling or unable to come onto site.

As the adoption of trial decentralisation rises, a number of challenges have presented themselves…

Contact Us
Send a message